Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors

Stromal Niche Cells Protect Early Leukemic FLT3-ITD+ Progenitor Cells against First-Generation FLT3 Tyrosine Kinase Inhibitors

(2011) A. Parmar et al.   CANCER RESEARCH

Comprehensive analysis of kinase inhibitor selectivity

(2011) Mindy I Davis et al.   NATURE BIOTECHNOLOGY

Survey of Activated FLT3 Signaling in Leukemia

(2011) Ting-lei Gu et al.   PLoS One

The JAK3-selective inhibitor PF-956980 reverses the resistance to cytotoxic agents induced by interleukin-4 treatment of chronic lymphocytic leukemia cells: potential for reversal of cytoprotection by the microenvironment

(2010) A. J. Steele et al.   BLOOD

Antitumor Activity of Targeting Src Kinases in Endothelial and Myeloid Cell Compartments of the Tumor Microenvironment

(2010) W. Liang et al.   CLINICAL CANCER RESEARCH

Smac mimetics: implications for enhancement of targeted therapies in leukemia

(2010) E Weisberg et al.   LEUKEMIA

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity

(2010) Douglas W McMillin et al.   NATURE MEDICINE

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

(2009) P. P. Zarrinkar et al.   BLOOD

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy

(2009) A. K. Azab et al.   BLOOD

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

(2009) A. V. Kurtova et al.   BLOOD

Spleen Tyrosine Kinase Is Overexpressed and Represents a Potential Therapeutic Target in Chronic Lymphocytic Leukemia

(2009) Maike Buchner et al.   CANCER RESEARCH

FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML

(2009) Ellen Weisberg et al.   DRUG RESISTANCE UPDATES

CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients

(2009) A Pardanani et al.   LEUKEMIA

Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells

(2008) E. Weisberg et al.   BLOOD

High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation

(2008) J. A. Burger et al.   BLOOD

Validation of PDGFR  and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib

(2008) A. M. L. Coluccia et al.   BLOOD

Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells

(2008) S Gobessi et al.   LEUKEMIA

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment

(2008) U Mony et al.   LEUKEMIA

Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells

(2008) E. Weisberg et al.   MOLECULAR CANCER THERAPEUTICS